Get started
Author

Sujata Arora

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
2019 · Panagiotis A. Konstantinopoulos, Steven Waggoner, et al. · JAMA Oncology · 564
PDF
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
2019 · Shaveta Vinayak, Sara M. Tolaney, et al. · JAMA Oncology · 454
PDF
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
2009 · David P. Steensma, Maria R. Baer, et al. · Journal of Clinical Oncology · 319
PDF
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
2019 · Josep M. del Campo, Ursula A. Matulonis, et al. · Journal of Clinical Oncology · 191
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
2015 · Lee S Schwartzberg, Manuel R Modiano, et al. · The Lancet Oncology · 153
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
2018 · Panagiotis A. Konstantinopoulos, Steven E. Waggoner, et al. · Journal of Clinical Oncology · 143
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
2015 · Bernardo L Rapoport, Martin R Chasen, et al. · The Lancet Oncology · 141
TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.
2018 · Shaveta Vinayak, Sara M. Tolaney, et al. · Journal of Clinical Oncology · 77
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind , Randomized, Placebo‐Controlled , Phase 2 Trial
2023 · Joan T. Merrill, Joel Guthridge, et al. · Arthritis & Rheumatology · 68
Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
2016 · Paul J. Hesketh, Ian D. Schnadig, et al. · Cancer · 67
PDF
The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Pharmacokinetics of β‐Carotene in Healthy Volunteers
1996 · Jianguo Zhi, Angela T. Melia, et al. · The Journal of Clinical Pharmacology · 66
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)
2015 · Bernardo Rapoport, Daniel Chua, et al. · Supportive Care in Cancer · 65
Growth, Systemic Safety, and Efficacy During 1 Year of Asthma Treatment With Different Beclomethasone Dipropionate Formulations: An Open-Label, Randomized Comparison of Extrafine and Conventional Aerosols in Children
2002 · Søren Pedersen, John Warner, et al. · PEDIATRICS · 65
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy
2016 · Bernardo Rapoport, Lee Schwartzberg, et al. · European Journal of Cancer · 48
PDF
The Influence of Reduced Dietary Fat Absorption Induced by Orlistat on the Pharmacokinetics of Digoxin in Healthy Volunteers
1995 · Angela T. Melia, Jianguo Zhi, et al. · The Journal of Clinical Pharmacology · 41
Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: A 6-month, open- label, randomized trial
2002 · Stanley J. Szefler, John Warner, et al. · Journal of Allergy and Clinical Immunology · 26
PDF
Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open‐Label Pivotal Study
2017 · Xiaodong Wang, Zhi‐Yi Zhang, et al. · The Journal of Clinical Pharmacology · 20
Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P‐glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers
2017 · Xiaodong Wang, Zhi‐Yi Zhang, et al. · The Journal of Clinical Pharmacology · 18
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
2016 · Martin Chasen, Laszlo Urban, et al. · Supportive Care in Cancer · 13
PDF
Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
2018 · Rudolph M. Navari, Bernardo L. Rapoport, et al. · Cancer Medicine · 12
PDF
Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects
2018 · Xiaodong Wang, Zhi‐Yi Zhang, et al. · The Journal of Clinical Pharmacology · 9
Pharmacokinetics, Pharmacodynamics, Bioavailability, and Immunogenicity of Obexelimab Following Subcutaneous Administration in Healthy Japanese and Non-Japanese Volunteers
2024 · Xiaodong Wang, Rachel Kirk, et al. · Advances in Therapy · 6
Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects
2018 · Xiaodong Wang, Zhi‐Yi Zhang, et al. · Clinical Pharmacology in Drug Development · 6
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC).
2015 · Paul Joseph Hesketh, Lee Steven Schwartzberg, et al. · Journal of Clinical Oncology · 5
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis
2025 · Xiaodong Wang, Minggeng Gao, et al. · Clinical Pharmacology in Drug Development · 4
Works count: 41
Citation count: 2,609
H-index: 18
I10-index: 20
Year
Topic
Type